Grünenthal Report 2024-2025

Grünenthal has a clear, bold vision: a World Free of Pain. In 2024, we took significant steps forward in developing innovative medicines for patients living with pain worldwide. The latest Grünenthal Report provides information about our key objectives and activities, recent business development highlights, and financial performance.

Grünenthal is a global leader in pain management and related diseases. We have a long track record of bringing innovative treatments to patients worldwide. As a fully integrated pharmaceutical company, we cover the entire value chain – from drug research and development to commercial isolation of portfolios with growth products and established medicines. We operate in accordance with the highest ethical and regulatory standards, and we focus our efforts on our vision of a World Free of Pain.